140 related articles for article (PubMed ID: 26299212)
1. Breast cancer and (25R)-26-hydroxycholesterol.
Javitt NB
Steroids; 2015 Dec; 104():61-4. PubMed ID: 26299212
[TBL] [Abstract][Full Text] [Related]
2. Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort.
Le Cornet C; Walter B; Sookthai D; Johnson TS; Kühn T; Herpel E; Kaaks R; Fortner RT
Breast Cancer Res; 2020 Feb; 22(1):23. PubMed ID: 32075687
[TBL] [Abstract][Full Text] [Related]
3. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles.
Javitt NB
J Lipid Res; 2002 May; 43(5):665-70. PubMed ID: 11971935
[TBL] [Abstract][Full Text] [Related]
4. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.
Nelson ER
Mol Cell Endocrinol; 2018 May; 466():73-80. PubMed ID: 28919300
[TBL] [Abstract][Full Text] [Related]
5. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.
Nelson ER; Wardell SE; Jasper JS; Park S; Suchindran S; Howe MK; Carver NJ; Pillai RV; Sullivan PM; Sondhi V; Umetani M; Geradts J; McDonnell DP
Science; 2013 Nov; 342(6162):1094-8. PubMed ID: 24288332
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.
Lindahl G; Saarinen N; Abrahamsson A; Dabrosin C
Cancer Res; 2011 Jan; 71(1):51-60. PubMed ID: 21097717
[TBL] [Abstract][Full Text] [Related]
7. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.
Kimbung S; Chang CY; Bendahl PO; Dubois L; Thompson JW; McDonnell DP; Borgquist S
Endocr Relat Cancer; 2017 Jul; 24(7):339-349. PubMed ID: 28442559
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
9. 27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.
He S; Nelson ER
Maturitas; 2017 Oct; 104():29-35. PubMed ID: 28923174
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
11. 27-Hydroxylation of oncosterone by CYP27A1 switches its activity from pro-tumor to anti-tumor.
Ayadi S; Friedrichs S; Soulès R; Pucheu L; Lütjohann D; Silvente-Poirot S; Poirot M; de Medina P
J Lipid Res; 2023 Dec; 64(12):100479. PubMed ID: 37981011
[TBL] [Abstract][Full Text] [Related]
12. [Response to tamoxifen in estrogen receptor-positive cell line MCF-7 is independent of p53 expression].
Shtam TA; Pantina RA; Varfolomeeva EIu; Filatov MV
Vopr Onkol; 2007; 53(2):194-9. PubMed ID: 17663174
[TBL] [Abstract][Full Text] [Related]
13. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
14. An alternative pathway of reverse cholesterol transport: the oxysterol 27-hydroxycholesterol.
Weingärtner O; Laufs U; Böhm M; Lütjohann D
Atherosclerosis; 2010 Mar; 209(1):39-41. PubMed ID: 19801147
[TBL] [Abstract][Full Text] [Related]
15. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production.
Bauman DR; Bitmansour AD; McDonald JG; Thompson BM; Liang G; Russell DW
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16764-9. PubMed ID: 19805370
[TBL] [Abstract][Full Text] [Related]
16. Liver X receptor as a drug target for the treatment of breast cancer.
Wu Y; Yu DD; Yan DL; Hu Y; Chen D; Liu Y; Zhang HD; Yu SR; Cao HX; Feng JF
Anticancer Drugs; 2016 Jun; 27(5):373-82. PubMed ID: 26872310
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and the Rafoxifene analog LY117018: their effects on arachidonic acid release from cells in culture and on prostaglandin I2 production by rat liver cells.
Levine L
BMC Cancer; 2004 Aug; 4():49. PubMed ID: 15310397
[TBL] [Abstract][Full Text] [Related]
18. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.
Wu Q; Ishikawa T; Sirianni R; Tang H; McDonald JG; Yuhanna IS; Thompson B; Girard L; Mineo C; Brekken RA; Umetani M; Euhus DM; Xie Y; Shaul PW
Cell Rep; 2013 Nov; 5(3):637-45. PubMed ID: 24210818
[TBL] [Abstract][Full Text] [Related]
19. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol, hydroxycholesterols, and bile acids.
Javitt NB
Biochem Biophys Res Commun; 2002 Apr; 292(5):1147-53. PubMed ID: 11969205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
